医療ガバナンス研究所

Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis

No.

Date:

Title:

31

​

Authors:

Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T

First Author:

Murayama A

Journal/Book:

Otolaryngol Head Neck Surg

URL:

https://pubmed.ncbi.nlm.nih.gov/34399654/

Japan’s conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA

No.

Date:

Title:

30

​

Authors:

Murayama A, Ueda M, Shrestha S, Tanimoto T, Ozaki A

First Author:

Murayama A

Journal/Book:

Cancer Cell

URL:

https://doi.org/10.1016/j.ccell.2021.07.008

The Coverage in England of US-Approved Cancer Drugs

No.

Date:

Title:

29

​

Authors:

Hashimoto T, Ozaki A, Tanimoto T

First Author:

Hashimoto T

Journal/Book:

JAMA Internal Medicine

URL:

https://doi.org/10.1001/jamainternmed.2021.3336

Accuracy of post-publication Financial Conflict of Interest corrections in medical research: a secondary analysis of pharmaceutical company payments to the authors of the CREATE-X trial report in the New England Journal of Medicine

No.

Date:

Title:

18

​

Authors:

Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

Bioethics

URL:

Industry Payments to Medical Oncologists

No.

Date:

Title:

28

​

Authors:

Hashimoto T, Ozaki A, Tanimoto T

First Author:

Hashimoto T

Journal/Book:

JAMA Oncology

URL:

https://jamanetwork.com/journals/jamaoncology/fullarticle/2780257?guestAccessKey=ae0a79bd-aa1f-43ba-a13b-721161dcc5c2&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaoncology&utm_content=olf&utm_term=052721

Japan’s Drug Regulation During the COVID‐19 Pandemic: Lessons From a Case Study of Favipiravir

No.

Date:

Title:

27

​

Authors:

Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M

First Author:

Ueda M

Journal/Book:

Clin Pharmacol Ther

URL:

https://pubmed.ncbi.nlm.nih.gov/33882157/

Opioids: A ‘crisis’ of too much or not enough – or simply how rich you are and where you live?

No.

Date:

Title:

26

​

Authors:

Miyachi T, Ozaki A, Saito H, Sawano T, Tanimoto T, Crump A

First Author:

Miyachi T

Journal/Book:

Eur J Pain

URL:

https://pubmed.ncbi.nlm.nih.gov/33822443/

Whistleblowing and Misconduct at Large Pharmaceutical Firms

No.

Date:

Title:

25

​

Authors:

Hashimoto T, Ozaki A, Tanimoto T

First Author:

Hashimoto T

Journal/Book:

The Journal of the American Medical Association

URL:

https://jamanetwork.com/journals/jama/article-abstract/2778123

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension

No.

Date:

Title:

24

​

Authors:

Senoo Y, Hiroaki S, Ozaki A, Sawano T, Shimada Y, Yamamoto K, Suzuki Y, Tanimoto T

First Author:

Senoo Y

Journal/Book:

Medicine

URL:

https://pubmed.ncbi.nlm.nih.gov/33761642/

Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017

No.

Date:

Title:

23

​

Authors:

Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, Senoo Y, Tanimoto T

First Author:

Harada K

Journal/Book:

Health Policy

URL:

https://doi.org/10.1016/j.healthpol.2020.12.005

Covid-19 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies.

No.

Date:

Title:

20

​

Authors:

Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Ranjit Sah, Tetsuya Tanimoto

First Author:

Anju Murayama

Journal/Book:

Clinical Microbiology and Infection

URL:

https://bit.ly/3aJGwuY

Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment

No.

Date:

Title:

21

​

Authors:

Kida Futa, Anju Murayama, Hiroaki Saito, Akihiko Ozaki, Yuki Shimada, Tetsuya Tanimoto

First Author:

Kida Futa

Journal/Book:

Liver International

URL:

https://bit.ly/2Nti0Wm

Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings

No.

Date:

Title:

22

​

Authors:

Masahiro Wada, Akihiko Ozaki, Takashi Miyachi, Tetsuya Tanimoto, Andy Crump

First Author:

Masahiro Wada

Journal/Book:

Investigational New Drugs

URL:

https://bit.ly/3bqkblC

Transparency is not enough: how can we improve the management of financial conflicts of interest between Pharma and healthcare domains?

No.

Date:

Title:

19

​

Authors:

Akihiko Ozaki, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Kayo Harada, Yuki Senoo, Kana Yamamoto, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

Clinical Pharmacology & Therapeutics

URL:

https://bit.ly/3dC6GSA

Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan

No.

Date:

Title:

17

​

Authors:

Kana Yamamoto, Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto

First Author:

Kana Yamamoto

Journal/Book:

International Urogynecology Journal

URL:

https://bit.ly/2Nmkt52

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan

No.

Date:

Title:

16

​

Authors:

Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto

First Author:

Anju Murayama

Journal/Book:

PLOS ONE

URL:

https://bit.ly/3bISGUz

Response to "Strictness and Transparency in Approval Process of Medical Products: Japanese Situation"

No.

Date:

Title:

15

​

Authors:

Toyoaki Sawano, Akihiko Ozaki, Hiroaki Saito, Yuki Shimada, Tetsuya Tanimoto

First Author:

Toyoaki Sawano

Journal/Book:

Clinical Pharmacology & Therapeutics

URL:

Overview and Transparency of Non-research Payments to Healthcare Organizations and Healthcare Professionals from Pharmaceutical Companies in Japan: Analysis of Payment Data in 2016

No.

Date:

Title:

14

​

Authors:

Akihiko Ozaki, Hiroaki Saito, Yuki Senoo, Toyoaki Sawano, Yuki Shimada, Yurie Kobashi, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

Health Policy

URL:

https://bit.ly/3bo4SK4

Pharmaceutical company payments to Japanese government drug regulation committee members

No.

Date:

Title:

13

​

Authors:

Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T

First Author:

Toyoaki Sawano

Journal/Book:

Clinical Pharmacology & Therapeutics

URL:

https://bit.ly/2Nvhjvx

Pharmaceutical Company Payments to the Professors of Orthopaedic Surgery Departments in Japan

No.

Date:

Title:

12

​

Authors:

Hiroaki Saito, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto

First Author:

Hiroaki Saito

Journal/Book:

Journal of Bone and Joint Surgery

URL:

https://bit.ly/3pBRreE

Japan's drug regulation framework: aiming for better health or bigger profits

No.

Date:

Title:

11

​

Authors:

Akihiko Ozaki, Yuki Senoo, Hiroaki Saito, Andy Crump, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

International Journal of Health Policy and Management

URL:

https://bit.ly/3dvGQzw

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?

No.

Date:

Title:

10

​

Authors:

Yurie Kobashi, Makoto Watanabe, Hideaki Kimura, Asaka Higuchi, Akihiko Ozaki

First Author:

Yurie Kobashi

Journal/Book:

International Journal of Health Policy and Management

URL:

https://bit.ly/3dC6liM

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis

No.

Date:

Title:

9

​

Authors:

Akihiko Ozaki, Hiroaki Saito, Yosuke Onoue, Toyoaki Sawano, Yuki Shimada, Yurie Somekawa, Aritsune Tsuji, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

BMJ Open

URL:

https://bit.ly/3seCJMk

Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan

No.

Date:

Title:

8

​

Authors:

Hiroaki Saito, Yuta Tani, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Tetsuya Tanimoto

First Author:

Hiroaki Saito

Journal/Book:

Clinical Microbiology and Infection

URL:

https://bit.ly/3sir8fb

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan

No.

Date:

Title:

7

​

Authors:

Toyoaki Sawano, Akihiko Ozaki, Hiroaki Saito, Yuki Shimada, Tetsuya Tanimoto

First Author:

Toyoaki Sawano

Journal/Book:

JAMA Network Open

URL:

https://bit.ly/3kan1ix

Transparency of clinical evidence for medical devices in Europe

No.

Date:

Title:

6

​

Authors:

Tetsuya Tanimoto, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Akihiko Ozaki

First Author:

Tetsuya Tanimoto

Journal/Book:

Lancet

URL:

https://bit.ly/2ZCFIC7

Evaluation of pharmaceutical company payments and conflict of interest disclosures among oncology clinical practice guideline authors in Japan

No.

Date:

Title:

5

​

Authors:

Hiroaki Saito, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Tetsuya Tanimoto

First Author:

Hiroaki Saito

Journal/Book:

JAMA Network Open

URL:

https://bit.ly/3dA7pU2

Pharmaceutical company payments to executive board members of professional medical associations in Japan

No.

Date:

Title:

4

​

Authors:

Hiroaki Saito, Akihiko Ozaki, Yasuma Kobayashi, Toyoaki Sawano, Tetsuya Tanimoto

First Author:

Hiroaki Saito

Journal/Book:

JAMA Internal Medicine

URL:

https://bit.ly/3pE6q7X

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016

No.

Date:

Title:

3

​

Authors:

Yuki Shimada, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto

First Author:

Yuki Shimada

Journal/Book:

Alzheimer's & Dementia: Translational Research & Clinical Interventions

URL:

https://bit.ly/2MeygtN

A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of medicine

No.

Date:

Title:

2

​

Authors:

Akihiko Ozaki, Morihito Takita, Tetsuya Tanimoto

First Author:

Akihiko Ozaki

Journal/Book:

Investigational New Drugs

URL:

https://bit.ly/3ufX7ym

Conflict of interest and the CREATE-X trial in the New England Journal of medicine

No.

Date:

Title:

1

​

Authors:

Akihiko Ozaki

First Author:

Akihiko Ozaki

Journal/Book:

Science and Engineering Ethics

URL:

https://bit.ly/37F0vcm